Previous 10 | Next 10 |
RAPT Therapeutics (NASDAQ: RAPT) stock was crushing it on Monday, with shares skyrocketing 110.4% as of 11:59 a.m. EDT. The huge gain came after the company announced positive top-line results from a phase 1b clinical study evaluating RPT193 in treating moderate-to-severe atopic der...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips RAPT Therapeutics (NASDAQ: RAPT ) stock is rocketing higher on Monday thanks to positive results from a recent clinical trial of RPT193. Source: Shutterstock RPT193 is the company’s treatment in develop...
Canberk Sezer/iStock via Getty Images RAPT Therapeutics ([[RAPT]] +106.5%) has reached its highest level since October 2020 after the company announced positive early-stage data for RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis ((AD)). In reaction, Cantor Fitzger...
Gainers: Enochian Biosciences ENOB +127%, RAPT Therapeutics RAPT +101%, iTeos Therapeutics ITOS +37%, Novan NOVN +30%, Anavex Life Sciences AVXL +23%.Losers: Avenue Therapeutics ATXI -39%, Inhibikase Therapeutics (IKT) -21%, ...
RAPT Therapeutics (RAPT) soars 99.6% premarket on positive topline results from Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis ((AD)). The RPT193 group showed clear improvement in key efficacy measures compared to placebo at...
• Improvements demonstrated in all key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeks following once-daily oral treatment with RPT193 • Further improvement in percent change in EAS...
SOUTH SAN FRANCISCO, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet n...
RAPT Therapeutics ([[RAPT]] -14.3%) is likely on track for its biggest one-day loss since November. The company’s insider sales have accelerated in May.Compared to April when insiders sold only ~2K company shares and bought 1.3K shares, in May, they have sold ~5.7K shares with no ...
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet ne...
RAPT Therapeutics (RAPT): Q1 GAAP EPS of -$0.66 misses by $0.04.Revenue of $1.22M (+29.8% Y/Y) beats by $0.54M.Press Release For further details see: RAPT Therapeutics EPS misses by $0.04, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
RAPT Therapeutics Inc. Company Name:
RAPT Stock Symbol:
NASDAQ Market:
RAPT Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflamm...
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflamm...
2024-02-23 01:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...